Estradiol Patch 0.075mg

Route: Transdermal patch.

• Apply to clean, dry, intact hairless skin on the lower abdomen, buttocks, or hip.
• Change on the prescriber-specified schedule (once-weekly or twice-weekly).
• Press firmly for 10 seconds; rotate application sites at each change.
• Remove prior patch before applying a new one; dispose of used patch safely.

0.075 mg/day is used when the 0.05 mg/day dose has not adequately controlled vasomotor or other estrogen-deficiency symptoms. Dosing is prescriber-directed:

• Typically titrated up from 0.05 mg/day after 4–8 weeks of inadequate symptom response.
• Women with an intact uterus require concurrent progestogen.
• Serum estradiol and symptom reassessment at 4–8 weeks after dose escalation.
• Further titration to 0.1 mg/day is possible for persistent severe symptoms.

• Estradiol (0.075 mg/day transdermal): At this dose, serum estradiol typically achieves mid-to-upper premenopausal follicular phase levels (~60–100 pg/mL). Binds ERα and ERβ with high affinity, driving robust genomic and non-genomic estrogenic signaling: thermoregulatory stabilization (hot flash suppression), osteoclast inhibition (bone density maintenance), vaginal mucosal proliferation (genitourinary syndrome treatment), serotonergic upregulation (mood), and endothelial NO production (vascular tone). Transdermal delivery avoids hepatic first-pass metabolism.

Clinical Context: The 0.075 mg/day patch is prescribed for patients with moderate-to-severe menopausal symptoms who have not achieved adequate relief at 0.05 mg/day, or for patients with higher estradiol requirements (younger postmenopausal women, surgical menopause, or those with rapid estradiol metabolism). It may also be considered for more pronounced bone protection goals when lower doses are insufficient. Bone density (DXA) monitoring at baseline and after 1–2 years of therapy is recommended if osteoporosis prevention is a primary goal.

Monitoring:

• Serum estradiol at 4–8 weeks; target 60–100 pg/mL range for this dose.
• Concurrent progestogen and endometrial surveillance in non-hysterectomized patients.
• Annual mammography; blood pressure; lipid panel as indicated.

Contraindications: Same as other estradiol transdermal preparations — estrogen-dependent malignancies, undiagnosed uterine bleeding, active VTE/PE/arterial thromboembolism, active liver disease, thrombophilic disorders, pregnancy.

Warnings & Precautions: Same as other systemic estrogen formulations — endometrial protection, breast cancer risk, thromboembolic risk, safe patch disposal. At higher doses, monitoring for signs of estrogen excess (breast tenderness, bloating, headache, nausea) is especially important.

Drug Interactions: Same as for other estradiol patches — CYP3A4 inducers/inhibitors; thyroid hormone monitoring.

Common Side Effects: Application site reactions, breast tenderness (more prominent at higher doses), headache, nausea, bloating, mood changes, and breakthrough spotting without adequate progestogen coverage.

Store below 30°C / 86°F; do not freeze. Keep in original sealed pouches. Store out of reach of children and away from humidity. Use before the beyond-use date assigned by Genesis Compounding.

Why was my dose increased from 0.05mg to 0.075mg?

If hot flashes or other symptoms were not adequately controlled at 0.05 mg/day after 4–8 weeks, the prescriber may increase to 0.075 mg/day to achieve a higher serum estradiol level. The goal is to use the lowest dose that effectively controls symptoms.

Will the higher dose increase my risks?

Higher doses provide more estrogen exposure, which may modestly increase risk of estrogen-dependent effects (breast stimulation, endometrial proliferation if progestogen is inadequate). The prescriber balances symptom control against individual risk factors. Annual mammography and endometrial monitoring are essential at this or any estrogen dose.

Can I go back to 0.05mg?

If symptoms are well-controlled and the prescriber agrees, dose reduction is possible. The prescriber will guide any dose changes based on symptom status and laboratory values.

Do I still need progestogen at this dose?

Yes — concurrent progestogen is required for all systemic estrogen doses in women with an intact uterus, regardless of dose strength. Progestogen requirement does not diminish at higher estrogen doses.

Is this FDA-approved?

FDA-approved estradiol patches at 0.075 mg/day exist. This is a patient-specific 503A compounded preparation from Genesis Compounding and is not itself FDA-approved as a compounded product.